FTLF FitLife Brands, Inc.
FitLife Brands, Inc. provides nutritional supplements and wellness products for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; general wellness products with an emphasis on natural, vegan, and organic ingredients; male health and weight loss products; energy products; general health supplements; and natural skincare and beauty products; supplements focused on targeted nutrition; supplements for weight loss, cleansing and sexual health, and total body wellness. It markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, Maritime Naturals, MusclePharm, Irwin Naturals, Applied Nutrition, and Nature's Secret through franchised stores, as well as through retail locations, which include specialty, mass, and online, and e-commerce platform. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.…
Industry Peers
Packaged FoodsKey Statistics
About FitLife Brands (NASDAQ: FTLF)
›
FitLife Brands (NASDAQ: FTLF) is listed on Nasdaq, where its shares trade in USD. It belongs to the Packaged Foods industry, part of the Consumer Defensive sector, and reports about 81 employees.
The shares were at 8.480 USD on 13 November 2026, down 55.3% over 52 weeks. Its 52-week range is 7.660 USD to 19.23 USD: the price is 55.9% below the high and 10.7% above the low.
At a market capitalisation of 79.64M USD, it trades at 13.7 times trailing earnings and 6.6 times forward earnings. The median trailing P/E of its 17 largest Packaged Foods peers is 25.4, a discount of 46% for FTLF.
FitLife Brands reports return on equity of 14.5%, an operating margin of 12.9% and revenue up 64.6% year over year.
Its debt exceeds its cash by 37.32M USD, a debt-to-equity ratio of 1.04. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 2 analysts cover the stock; their mean price target of 17.50 USD is 106.4% above the current price. The next earnings report is expected on 16 November 2026.